Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

The FDA is continuing its push to expedite early-stage research for drug developers and is now accepting applications for a new pilot program aimed at accelerating U.S. clinical trials. The primary ...

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.